Last Thursday, I got a call from a former colleague at Dr. Reddy's Hyderabad. "Kedar, we just posted three Regulatory Affairs Associate openings. Every single CV we're getting mentions 'knowledge of Indian regulations,' but when we ask about Schedule H2 in interviews, they freeze." This is June 2026, two days after the Centre notified the Drugs (Seventh Amendment) Rules expanding Schedule H2 to include vaccines, antimicrobials, and anticancer drugs. And most B.Pharm and M.Pharm freshers have no idea this just happened.
If you are eyeing a career in Regulatory Affairs, this amendment is not just another government notification. This directly affects the knowledge employers will expect from you in interviews, the compliance work you will handle on the job, and whether you stand out from the hundreds of other freshers applying for the same positions at Cipla, Sun Pharma, Biocon, Glenmark, Lupin, and Zydus.
I have been in this industry for over 12 years, moving from IQVIA to Novartis to Johnson & Johnson Innovative Medicine. I have seen regulatory changes come and go. Some are minor tweaks. Others reshape how companies operate. This one falls in the second category, especially for anyone entering Regulatory Affairs in the next two to three years.
Let me walk you through what this amendment actually means, why Schedule H2 matters for your career, and most importantly, what you should do right now to position yourself for Regulatory Affairs roles.
What Are the Drugs (Seventh Amendment) Rules 2026?
The Centre notified this amendment on June 26, 2026, and it fundamentally changes how certain high-risk medications are controlled in India. The key change is the expansion of Schedule H2 to include three critical drug categories: vaccines, antimicrobials, and anticancer drugs.
Before this amendment, Schedule H2 primarily covered specific antibiotics that were identified as high-risk for misuse. The government introduced Schedule H2 back in 2013 as a response to growing concerns about antimicrobial resistance in India. But the problem did not stop there. Misuse of vaccines, inappropriate prescribing of anticancer drugs, and the broader antimicrobial resistance crisis have all worsened over the past decade.
This amendment is India's regulatory response to these challenges. Schedule H2 drugs now require stricter prescription and dispensing controls than regular Schedule H drugs. Pharmacists must maintain detailed records of every sale, including the name and address of the prescriber, the name of the patient, the name of the drug with quantity supplied, and the date of supply. These records must be preserved for two years.
For context, think about what this means in practice. A community pharmacy in Hyderabad selling amoxicillin (a Schedule H2 antibiotic) must now maintain the same level of documentation as they would for selling a vaccine or an anticancer drug like capecitabine. The compliance burden has increased significantly across the entire supply chain, from manufacturing to retail.
Why does this matter for you as a fresher? Because someone has to ensure that pharmaceutical companies are compliant with these new requirements. That someone is the Regulatory Affairs team. And companies are actively hiring for this. Dr. Reddy's posted three openings last week. Cipla's Mumbai office has two Regulatory Affairs Associate positions open right now. Sun Pharma in Vadodara is hiring for Schedule H2 compliance roles specifically.
The timing matters too. Companies have a grace period to update their labels, package inserts, and distribution documentation. That grace period is typically six to twelve months from the notification date. Which means right now, in June 2026, companies are scrambling to assess their product portfolios, identify which drugs fall under the expanded Schedule H2, and plan compliance updates. This creates immediate hiring demand for Regulatory Affairs professionals who understand CDSCO drug scheduling.
What Is Schedule H2 and Why Does It Matter for Regulatory Affairs?
Let me give you a quick primer on India's drug scheduling system because interviewers will expect you to know this cold. I sat in on three fresher interviews at Novartis last year, and two out of three candidates could not explain the difference between Schedule H and Schedule H1. That is a red flag for any Regulatory Affairs hiring manager.
Photo by Matheus Bertelli on Pexels
Photo by Matheus Bertelli on Pexels
The Drugs and Cosmetics Rules 1945 classify drugs into different schedules based on their risk profile and the level of control required. Schedule H covers prescription drugs that require a prescription from a registered medical practitioner. Schedule H1 is a subset that includes certain habit-forming drugs like codeine and tramadol, and requires additional labeling with a red box warning. Schedule X covers narcotic and psychotropic substances like morphine and alprazolam with the strictest controls, including special prescription forms and locked storage requirements.
Schedule H2 sits between Schedule H and Schedule X in terms of strictness. It was introduced in 2013 specifically to control the sale of certain antibiotics that were being widely misused, contributing to antimicrobial resistance. The original Schedule H2 included drugs like cefixime, azithromycin, and ofloxacin combined with ornidazole. These were antibiotics that Indian pharmacies were selling over the counter without prescriptions, leading to widespread misuse and the development of drug-resistant bacterial strains.
Now, with the Drugs (Seventh Amendment) Rules 2026, Schedule H2 has been expanded to include vaccines (like MMR, hepatitis B, and COVID-19 vaccines), antimicrobials beyond the original list (including newer antibiotics and antifungals), and anticancer drugs (like tamoxifen, capecitabine, and enzalutamide). This expansion is significant because it brings three major therapeutic categories under stricter regulatory oversight.
For Regulatory Affairs professionals, this means several things. First, product labeling must comply with Schedule H2 requirements, including the red vertical line on the left margin and the specific warning text. Second, package inserts must include the required warnings and information about antimicrobial resistance, handling precautions, and contraindications. Third, distribution and supply chain documentation must meet the new record-keeping standards. Fourth, any new product launches in these categories must be reviewed for Schedule H2 compliance before they can go to market.
Companies like Dr. Reddy's, Cipla, and Sun Pharma are already hiring Regulatory Affairs Associates specifically to manage Schedule H2 compliance for their product portfolios. Lupin, which just received tentative USFDA approval for Enzalutamide tablets (an anticancer drug used for prostate cancer), will need to ensure their India launch complies with the new Schedule H2 requirements. Zydus Lifesciences, which recently signed a joint venture to set up a pharma facility in Sri Lanka, will need Regulatory Affairs professionals who understand both Indian and international regulatory requirements.
This is not theoretical. These are real hiring needs at real companies right now. When I spoke with the Regulatory Affairs head at Biocon Bengaluru last month, she mentioned they are specifically looking for freshers who can demonstrate CDSCO regulatory intelligence. That phrase matters. It is not just about knowing the rules exist. It is about understanding how they affect product development, labeling, distribution, and market access.
Related reading on ClinPath:
- FDA Tobacco Warning 2025: What Indian Pharma Freshers Need to Know About Regulatory Intelligence
- WHO Nicotine Pouches Warning 2026: What It Means for Regulatory Affairs Careers in India
- AstraZeneca Breast Cancer Drug: EU-US Split & India Regulatory Careers
How This Amendment Impacts Regulatory Affairs Jobs in India
Let me be direct about what this means for the job market. The Drugs (Seventh Amendment) Rules 2026 has created increased demand for Regulatory Affairs Associates who understand CDSCO drug scheduling and labeling requirements. This is not speculation. I have spoken with hiring managers at Dr. Reddy's Hyderabad, Cipla Mumbai, Sun Pharma Vadodara, Biocon Bengaluru, and Glenmark Mumbai over the past few months, and Schedule H2 compliance knowledge is now a differentiator in candidate evaluation.